A Clinical Study of MIL95 in Advanced Malignancies.
Primary Purpose
Advanced Malignancies
Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Recombinant Humanized Monoclonal Antibody MIL95
Sponsored by

About this trial
This is an interventional treatment trial for Advanced Malignancies
Eligibility Criteria
Inclusion Criteria:
- Adult patients, >=18 years of age;
- Diagnosis of Refractory/relapsed lymphomas or solid tumor;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Life expectancy >=3 months;
- Sufficient organ and bone marrow function;
- At least one measurable lesion or evaluable lesion (recist v1.1 or Lugano 2014);
- Able and willing to provide written informed consent and to comply with the study protocol.
Exclusion Criteria:
- Prior use of any anti-cancer therapy(including chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc) within 4 weeks of study start;
- Previous exposure to any drug targeting CD47 or SIRPα;
- Major surgery within 4 weeks prior to the first administration or expected to undergo major surgery during the study treatment;
- Live attenuated vaccine administrated within 4 weeks before the first administration or during the study period;
- Central nervous system metastasis;
- History of other primary malignant tumors in 5 years;
- Evidence of significant, uncontrolled concomitant disease;
- Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C(including HBsAg,HBcAb positive with abnormal HBV DNA or HCV RNA );
- Active or suspected autoimmune diseases;
- Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) while participating in the study; 2) for at least 12 months after discontinuation of all study treatments;
- Known history of hemolytic anemia;
- Known severe allergic reaction or/and infusion reaction to monoclonal antibody.
Sites / Locations
- Beijing Cancer HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
MIL95
Arm Description
Outcomes
Primary Outcome Measures
Percentage of Participants with Adverse Events
Percentage of Participants with AEs and SAEs assessed by NCI CTCAE v5.0.
Secondary Outcome Measures
Pharmacokinetics:AUC
The area under the curve (AUC) of serum concentration of the drug after the administration
Pharmacokinetics: Cmax
Maximum concentration(Cmax) of the drug after administration
Objective response rate (ORR)
To evaluate preliminary anti-tumor activity of MIL95 in subjects with advanced malignancies.ORR includes complete remission(CR) and partial remission(PR) assessed by RECIST v1.1 criteria for solid tumors and Lugano2014 criteria for lymphoma.
Duration of response (DoR)
DOR is defined as the time from the initial response (CR or PR) to the time of disease progression or death, whichever occurs first.
Progression free survival (PFS)
Defined as the time from the first day of study treatment to disease progression or death, whichever occurs first.
Immunogenicity
Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity of MIL95.
Full Information
NCT ID
NCT04651348
First Posted
November 11, 2020
Last Updated
October 19, 2023
Sponsor
Beijing Mabworks Biotech Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04651348
Brief Title
A Clinical Study of MIL95 in Advanced Malignancies.
Official Title
A Phase I Clinical Study of Recombinant Humanized Monoclonal Antibody MIL95 Injection in the Treatment of Lymphomas and Advanced Malignant Solid Tumors
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 4, 2021 (Actual)
Primary Completion Date
December 8, 2022 (Actual)
Study Completion Date
November 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beijing Mabworks Biotech Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study is composed of two stages: Part A initial dose escalation and Part B maintenance dose escalation. Both parts will adopt the classical 3+3 dose escalation design.
The starting dose for phase Ia part A is 0.1 mg/kg QW, followed by 3 dose cohorts (0.3mg/kg QW, 0.8mg/kg QW and 1mg/kg QW). Duration of dose limiting toxicity (DLT) observation is 14 days.
Part B will have 5 dose cohorts(3mg/kg QW, 10mg/kg QW, 20mg/kg QW 30mg/kg QW and 45mg/kg QW). DLT observation period is 28 days. The subject number for each cohort in Part B will be increased to 6 if the subject number enrolled in each cohort is less than 6.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Malignancies
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
58 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
MIL95
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Recombinant Humanized Monoclonal Antibody MIL95
Intervention Description
PART A :The patients confirming to the eligibility criteria will be assigned to the 4 dose groups (0.1mg/kg, 0.3mg/kg, 0.8mg/kg, 1.0mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL95 every week on Day 1 for a maximum of Twelve weeks.
PART B:One recommended dose as a priming dose will be selected from 4 dose groups(0.1mg/kg、0.3mg/kg、0.8mg/kg、1.0mg/kg) based on results of PART A. Each patient will receive a priming dose of MIL95 on Day 1 Cycle 1.The patients will be assigned to the 5 maintenance dose groups (3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 45mg/kg, respectively) based on the sequence of inclusion. The maintenance dose was given on Day 8,15,22 Cycle 1 and on Day 1,8,15,22 Cycle 2+. Each cycle was 28 days.
Primary Outcome Measure Information:
Title
Percentage of Participants with Adverse Events
Description
Percentage of Participants with AEs and SAEs assessed by NCI CTCAE v5.0.
Time Frame
up to 1year after enrollment
Secondary Outcome Measure Information:
Title
Pharmacokinetics:AUC
Description
The area under the curve (AUC) of serum concentration of the drug after the administration
Time Frame
up to 1year after enrollment
Title
Pharmacokinetics: Cmax
Description
Maximum concentration(Cmax) of the drug after administration
Time Frame
up to 1year after enrollment
Title
Objective response rate (ORR)
Description
To evaluate preliminary anti-tumor activity of MIL95 in subjects with advanced malignancies.ORR includes complete remission(CR) and partial remission(PR) assessed by RECIST v1.1 criteria for solid tumors and Lugano2014 criteria for lymphoma.
Time Frame
up to 1year after enrollment
Title
Duration of response (DoR)
Description
DOR is defined as the time from the initial response (CR or PR) to the time of disease progression or death, whichever occurs first.
Time Frame
up to 1year after enrollment
Title
Progression free survival (PFS)
Description
Defined as the time from the first day of study treatment to disease progression or death, whichever occurs first.
Time Frame
up to 1year after enrollment
Title
Immunogenicity
Description
Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity of MIL95.
Time Frame
up to 1year after enrollment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients, >=18 years of age;
Diagnosis of Refractory/relapsed lymphomas or solid tumor;
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Life expectancy >=3 months;
Sufficient organ and bone marrow function;
At least one measurable lesion or evaluable lesion (recist v1.1 or Lugano 2014);
Able and willing to provide written informed consent and to comply with the study protocol.
Exclusion Criteria:
Prior use of any anti-cancer therapy(including chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc) within 4 weeks of study start;
Previous exposure to any drug targeting CD47 or SIRPα;
Major surgery within 4 weeks prior to the first administration or expected to undergo major surgery during the study treatment;
Live attenuated vaccine administrated within 4 weeks before the first administration or during the study period;
Central nervous system metastasis;
History of other primary malignant tumors in 5 years;
Evidence of significant, uncontrolled concomitant disease;
Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C(including HBsAg,HBcAb positive with abnormal HBV DNA or HCV RNA );
Active or suspected autoimmune diseases;
Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) while participating in the study; 2) for at least 12 months after discontinuation of all study treatments;
Known history of hemolytic anemia;
Known severe allergic reaction or/and infusion reaction to monoclonal antibody.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yuqin Song, doctor
Phone
(+86)010-88121122
Email
songyuqin622@163.com
Facility Information:
Facility Name
Beijing Cancer Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuqin Song, doctor
12. IPD Sharing Statement
Learn more about this trial
A Clinical Study of MIL95 in Advanced Malignancies.
We'll reach out to this number within 24 hrs